Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers

Clinical Cancer Research

Volumn 12, Issue 5, 2006, Pages 1599-1605

  Adams, Gregory P ^a   Tai, Mei Sheng ^b   McCartney, John E ^b   Marks, James D ^e   Stafford III, Walter F ^d   Houston, L L ^f   Huston, James S ^b,c   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b CURIS INC   (United States)

^c EMD SERONO INC   (United States)

^d BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HOMODIMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DISULFIDE BOND; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY METABOLISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SCID MOUSE; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; DIMERIZATION; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, INBRED ICR; MICE, SCID; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 33645071568     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2217     Document Type: Article

References (34)

1. Chester K, Pedley B, Tolner B, et al. Engineering antibodies for clinical applications in cancer. Tumour Biol 2004;2:91-8.
2. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotny J. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E coli. Proc Natl Acad Sci U S A 1988;85:5879-83.
3. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science 1988;242:423-6.
4. Adams GP, McCartney JE, Tai M-S, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-34.
5. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Bri J Cancer 1998;77:1405-12.
6. Tai M-S, McCartney JE, Adams GP, et al. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res (Suppl) 1995;55:5983-9s.
7. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-6.
8. Kraus MH, Popeseu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related protooncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6:605-10.
9. van de Vijver M, vsn de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987;7:2019-23.
10. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
11. Yokota T, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988;2:283-7.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
13. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-9.
14. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
15. Colcher D, Bird R, Roselli R, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990;82:1191-7.
16. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-71.
17. Tai M-S, Mudgett-Hunter M, Levinson D, et al. A bifunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino terminal to anti-digoxin single-chain Fv. Biochemistry 1990;29:8024-30.
18. George AJT, Jamar F, Tai M-S, et al. Radiometal labeling of recombinant proteins by a genetically engineered, minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci U S A 1995;92:8358-62.
19. (Publisher's correction to Fig. 4: ibid 1996;93:9991.)
20. Adams GP, McCartney JE, Wolf EJ, et al. Enhanced tumor specificity of 741F8-1 (sFv′)2, an anti-C-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J Nucl Med 1995;36:2276-81.
21. McCartney JE, Tai M-S, Hudziak RM, et al. Engineering disulfide-linked single-chain Fv dimers [(sFv′)2] with improved solution and targeting properties: antidigoxin 26-10 (sFv′)2 and anti-c-erbB-2 741F8 (sFv′)2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Eng 1994;18:301-14.
22. Brennan M, Davidson PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985;229:81-3.
23. Schier R, Marks JD, Wolf E, et al. In vitro and in vivo characterization of a human anti-c-erB2 single chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995;1:73-81.
24. Adams GP, DeNardo SJ, Amin A, et al. Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody. Antibody Immunoconj Radiopharm 1992;5:81-95.
25. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
26. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (Suppl) 1990;50:814-9s.
27. Adams GP, McCartney JE, Wolf EJ, et al. Optimization of in vivo tumor targeting of monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv, effects of dose escalation and repeated i v. administration. Cancer Immunol Immunother 1995;40:299-306.
28. Weiner LM, Houston LL, Huston JS, et al. Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Target 1995;1:51-60.
29. Wu AM, Chen W, Raubitschek, et al. Tumor localization of anti-CEA single chain Fvs: improved targeting by non-covalent dinners. Immunotechnology 1996;221-36.
30. Reynolds JA. Interaction of divalent antibody with cell surface antigens. Biochemistry 1979;18:264-9.
31. Van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 1991;48:738-43.
32. Flynn AA, Boxer GM, Begent RH, Pedley RB. Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother 2001;50:77-81.
33. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 2001;61:4750-5.
34. 2 divalent form of anti-c-erbB2 single-chain Fv. Cell Biophys 1994;24/25:267-78.